Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease

Archives of Disease in Childhood

Volumn 93, Issue 2, 2008, Pages 142-146

  Furukawa, T ^a   Kishiro, M ^a   Akimoto, K ^a   Nagata, S ^a   Shimizu, T ^a   Yamashiro, Y ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HEPARIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; GLUCOCORTICOID;

ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; EMBOLISM; FEMALE; HUMAN; HYPERTENSION; HYPOTHERMIA; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RECURRENT FEVER; SINGLE DRUG DOSE; SINUS BRADYCARDIA; TREATMENT RESPONSE; CLINICAL PROTOCOL; DRUG COMBINATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ASPIRIN; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; CORONARY ANEURYSM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLATELET AGGREGATION INHIBITORS; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 38849166744     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.126144     Document Type: Article

References (28)

1. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febril mucocutaneous lymph node syndrome (MCLS) prevailing in Japan. Pediatrics 1974;54:271-6.
2. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
3. Furusho K, Nakano H, Shinomata K, et al. High-dose intravenous gamma globulin for Kawasaki disease. Lancet 1984;2:1055-8.
4. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8.
5. Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gamma globulin treatment failure in Kawasaki disease. Pediatrics 2000;105:e78.
6. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. Circulation 2004;110:2747-71.
7. Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9.
8. Dale RC, Saleem MA, Daw S, et al. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000;137:723-6.
9. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease. Pediatr Int 2001;43:211-17.
10. 2 synthase-type 2 in Kawasaki disease. J Infect Dis 2000;181:1101-9.
11. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-4.
12. Raman V, Kim J, Sharkey A, et al. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J 2001;20:635-7.
13. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
14. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
15. Kijima Y, Kimiya T, Suzuki A, et al. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982;46:1239-42.
16. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465-9.
17. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611-6.
18. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7.
19. Jibiki T, Terai M, Kurosaki T, et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur J Pediatr 2004;163:229- 33.
20. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-41.
21. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-75.
22. Japan Kawasaki Disease Research Committee. Diagnostic guidelines of Kawasaki disease. 4th rev edn. Tokyo: Japan Kawasaki Disease Research Committee, 1984.
23. Harada K. Intravenous γ-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 199;41:805-10.
24. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7.
25. Suzuki N, Seguchi M, Kouno C, et al. Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int 1999;41:318-20.
26. Longencker JP, Killty LA, Johnson LK. Glucocorticoid influence on growth of vascular wall cells in culture. J Cell Physiol 1982;113:197-202.
27. Baylis EM, Williams IA, English J, et al. High dose intravenous methylprednisolone "pulse" therapy in patients with rheumatoid disease. Plasma methylprednisolone levels and adrenal function. Eur J Clin Pharmacol 1982;21:385-8.
28. Ito S, Kusunoki Y, Oka T, et al. Yoshioka H. Pharmacokinetics of high-dose methylprednisolone in children. Dev Pharmacol Ther 1992;19:99-105.